In a more recent study (n = 193 patients), a panel of the plasma hypermethylation markers ALX4, bone morphogenetic protein 3 (BMP3), neuronal pentraxin 2 (NPTX2), retinoic acid receptor beta (RARB), syndecan 2 (SDC2), SEPT9, and VIM analyzed with MSP showed a sensitivity of 91% for stage I–IV and 89% for stage I–II CRC using a multifactorial model accounting for sex and age (67). This evidence concerns the gene NPTX2 and colorectal carcinoma.